Roche Lifts Swiss SMI as ABB Sells Off

That was visible in the day’s sector split. ABB fell 5.4% despite beating quarterly expectations and lifting its full-year targets slightly, a sign that strong results were not enough to overcome the market’s growing aversion to industrial cyclicals. AMS Osram dropped 5.7%, VAT lost 2.6% and Inficon fell 3.3%, reflecting pressure on technology and capital goods shares as investors worried about the impact of expensive energy, inflation and rising borrowing costs on growth-sensitive earnings.

Roche’s support for the index was especially important because Swiss equities have been drawing relative strength from defensives while broader European markets weakened more sharply. The DAX, CAC 40 and FTSE 100 were each down more than 1% in the latest session, while Brent crude briefly pushed above $110 a barrel, its highest level since May. That combination tends to reward companies with stable earnings, pricing power and less direct exposure to the cycle.

For investors, the message is twofold. On the bullish side, the Swiss market remains one of Europe’s more resilient places to hide when macro risks rise, and the coming results from Roche, Nestlé, Schindler, Galderma and Kühne+Nagel could reinforce that defensive appeal. On the bearish side, the market’s stability is being carried by a narrow group of heavyweight stocks, while industrial and tech names are increasingly vulnerable to any further spike in energy costs or yields.

The near-term test is whether Roche and its defensive peers can keep cushioning the index if global risk sentiment deteriorates again. If they do, the SMI may continue to outperform peers on a relative basis even without a broad rally. If they do not, the market’s narrow leadership could leave Swiss equities exposed to the same valuation pressure hitting the rest of Europe.